A case of keratoacanthoma in a patient receiving sorafenib for the treatment of hepatocellular carcinoma, which showed spontaneous disappearance after discontinuing sorafenib

DOI Web Site Web Site 29 References Open Access

Bibliographic Information

Other Title
  • 肝細胞癌に対するソラフェニブ投与中にケラトアカントーマを合併し，休薬により消褪した1例
  • 症例報告 肝細胞癌に対するソラフェニブ投与中にケラトアカントーマを合併し,休薬により消褪した1例
  • ショウレイ ホウコク カン サイボウ ガン ニ タイスル ソラフェニブ トウヨ チュウ ニ ケラトアカントーマ オ ガッペイ シ,キュウヤク ニ ヨリ ショウタイシタ 1レイ

Search this article

Description

<p>A 68-year-old man with advanced hepatocellular carcinoma had undergone hepatic arterial infusion chemotherapy since April 2015. However, the tumor increased in size in September 2015. Serum AFP and PIVKA II levels were also elevated. Five months after administration of sorafenib, hyperkeratotic papule appeared on his left of upper lip. Excisional biopsy confirmed the clinical diagnosis of Keratoacanthoma (KA). KA had disappeared 3 months after discontinuing sorafenib. Although KA and squamous cell carcinoma (SCC) have been reported to occur in 6-13.5% of the patients treated with sorafenib, the development of KA or SCC associated with sorafenib is rare in Japan. We recommend careful dermatologic monitoring of these patients to ensure early detection of KA or SCC.</p>

Journal

  • Kanzo

    Kanzo 58 (4), 248-254, 2017

    The Japan Society of Hepatology

References(29)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top